TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03242018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 200 mg, tablet, orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 200 mg, tablet, orally, once daily.
Study: NCT02032641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
Study: NCT04148612

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Opti-Me
Description: Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
Study: NCT02597127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PCSSC
Description: ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
Study: NCT01555515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implantation of autologous skin graft after ex-vivo treatment
Description: Subcutan implantation of autologous skin graft after ex-vivo treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutan implantation of autologus skin graft after ex-vivo treatment
Description: Subcutan implantation of autologus skin graft after ex-vivo treatment
Study: NCT04867941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
Study: NCT04336982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90009
Description: Injection
Study: NCT04867941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
Study: NCT04336982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Tablet
Study: NCT02741882

Intervention type: OTHER
Intervention: Questionary
Description: Questionary with clinical, demographic and behavior outcomes at the pregnancy period

Intervention type: OTHER
Intervention: Questionary
Description: Questionary with clinical, demographic and behavior outcomes at the pregnancy period
Study: NCT03047018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program
Description: The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
Study: NCT01312649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental psychology methods (computer tests)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental psychology methods (computer tests)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental psychology methods (computer tests)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental psychology methods (computer tests)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental psychology methods (computer tests)
Study: NCT02258555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9901
Description: GS-9901 tablets administered orally
Study: NCT02278250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 10 mg BIW
Description: Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 20 mg BIW
Description: Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 40 mg BIW
Description: Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 80 mg BIW
Description: Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 160 mg BIW
Description: Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 300 mg BIW
Description: Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study: NCT02597127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PCSSC
Description: ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Saline (sterile, normal, 0.9%) solution given as SC injections
Study: NCT03738059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: will receive intravenous Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: will receive intravenous Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: will receive intravenous Dexmedetomidine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9%
Description: will receive intravenous normal saline 0.9%
Study: NCT03110445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVV-740CTA
Description: non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
Study: NCT04500340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for test anxiety
Description: The cognitive-behavioral therapy protocol developed by Flaxman, Bond \& Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
Study: NCT04147598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LFD
Description: Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LFD
Description: Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAD
Description: Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAD
Description: Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
Study: NCT03050515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
Study: NCT02597127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Saline (sterile, normal, 0.9%) solution given as SC injections
Study: NCT04574440

Intervention type: DEVICE
Intervention: multichannel fNIRS monitoring
Description: Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap that will be positioned on the patient's head according to international operational guidelines and will be secured to the temporal region of the patient's forehead. The NIRS cap is entirely non-invasive and does not pose any additional risk to the patient. Monitoring will be commenced prior to the induction of anesthesia. Subsequent surgical and medical care will not be affected.
Study: NCT00840489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1000-1200 mg qd for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg bd for 24 weeks
Study: NCT03775057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyDoseCoach app
Description: The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
Study: NCT00845169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm vascular study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm vascular study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
Study: NCT00415103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
Study: NCT00651326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Study: NCT00415103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetrón: 0.25 mg iv every 48 hours, starting day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
Study: NCT02592174

Intervention type: OTHER
Group type: OTHER
Intervention: Health related quality of life and social and demographic informations
Description: At the inclusion visit with a self-assessment questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Neurocognitive assessment
Description: At the neurocognitive visit, with standard test as CONSTANCES cohort

Intervention type: RADIATION
Group type: OTHER
Intervention: cerebral images sub-study
Description: Standard magnetic resonance imaging
Study: NCT01486628

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ND0612
Description: levodopa and carbidopa solution for subcutaneous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for SC continuous administration
Study: NCT02174055

Intervention type: BEHAVIORAL
Intervention: Patient Interviews
Description: participate in a brief interview

Intervention type: BEHAVIORAL
Intervention: newly developed questionnaire
Description: 10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.

Intervention type: BEHAVIORAL
Intervention: Pilot Testing the Draft Measure
Description: The draft measure (approximately 35 items, described above) will be administered to a large sample of older cancer patients (n=150) to generate data to evaluate preliminary psychometric properties (item properties including measures of central tendency, skewness/kurtosis, internal consistency, test/re-test reliability, and construct validity (i.e, convergent and discriminant).and known group differences) to further winnow the measure to include approximately 20 items.
Study: NCT00913367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride + insulin glargine (Amaryl + Lantus)
Description: * Amaryl® 4 mg at breakfast + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)
Description: * Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast
Study: NCT04902456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Power chain and Crimpable hook fro En-masse Retraction
Description: Retraction will start on a 0.017x0.025 stainless steel wire using elastomeric chain ( for applied will be 212 g per side ) extending between the cripmable hooks and the miniscrew

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-loop
Description: closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine.
Study: NCT03366402

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR H1N1
Description: At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR H1N1
Description: At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
Study: NCT00651326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Study: NCT05309564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Single intervention
Study: NCT03523975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12
Study: NCT04243187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chilean Native Beans
Description: In each visit the participant would have to:~1. Fill a survey of gastrointestinal symptoms and basal bowel movements (THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS))~2. Fill a survey of food consumption~3. Bean plate intake~4. Expired hydrogen test, which consists of exhaling air in a syringe every 20 minutes for 12 times (4 hours in total). During this time the participant can do quiet activities (not physical activity).~5. Fill surveys of gastrointestinal symptoms (online or on paper), during the hydrogen test, at 12 and 24 hours (3 times). During this time (1 day before and 2 days later) the participant cannot eat other bloating foods (legumes, cauliflower, broccoli, lettuce, cabbage, artichokes, onions, topinambur and others described in the food survey).
Study: NCT00528398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study: NCT01408914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher-Dose Rifampin
Description: The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher-Dose Rifampin
Description: The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
Study: NCT00819351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG Asparaginase at six weeks interval
Description: PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG Asparaginase at two weeks interval
Description: PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
Study: NCT03417453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Drop Dispenser TYPE Opticare
Description: Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Drop Dispenser Autodrop
Description: Eye Drop Dispenser Autodrop
Study: NCT02730325

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum-derived bovine immunoglobulin/protein isolate (SBI)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02158338

Intervention type: OTHER
Intervention: Asthma
Description: mothers who have children that have been diagnosed with respiratory issues

Intervention type: OTHER
Intervention: Non-asthma
Description: mothers who have children that do not have a diagnosis of respiratory problems
Study: NCT03688477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera°
Description: iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
Study: NCT02395900

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Study: NCT04127331

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care Ultrasound
Description: Portable ultrasonography done at the bedside.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care Ultrasound
Description: Portable ultrasonography done at the bedside.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-Care Ultrasound
Description: Portable ultrasonography done at the bedside.